ライフサイエンスコーパス: follow-up

1 inically stable COPD patients (4-year median follow-up).

2 005 to December 31, 2013 were included (100% follow-up).

3 SRCTN10356387, and is currently in long-term follow up.

4 s 65 and 54% remained on TG until the end of follow-up.

5 est CT and spirometry at baseline and 5-year follow-up.

6 ncidence and mortality throughout the entire follow-up.

7 predict persistent respiratory morbidity at follow-up.

8 l index, 0.66 [+/-0.15]), 40 (91%) completed follow-up.

9 d 253 developed HCC during a mean of 9 years follow-up.

10 ukast, as well as between baseline and after follow-up.

11 VL on histology-confirmed CIN2+ detection at follow-up.

12 atient had no clinical complaints at routine follow-up.

13 data were collected at enrolment and during follow-up.

14 sequent cardiovascular events during 2 years follow-up.

15 the end of up-dosing, and after 6 months of follow-up.

16 g showed PD, and one participant was lost to follow-up.

17 respectively) with a median of 4.6 years of follow-up.

18 andomization and maintained during long-term follow-up.

19 s achieved in 53% of patients at 3 months of follow-up.

20 nonsignificantly attenuated over 5 years of follow-up.

21 mation on metastases were extracted from the follow-up.

22 ber 31, 2017, and this was the final date of follow-up.

23 ease progression over the 6.5 study years of follow-up.

24 Ten patients returned 2 weeks later for follow-up.

25 target the most suitable intervention during follow-up.

26 ttachment without any further surgery during follow-up.

27 s 3 and 4 for plasma sTNFR1 died over 4-year follow-up.

28 erall, 356 individuals completed 20 years of follow-up.

29 through December 31, 2015, the final day of follow-up.

30 with poor disease-free survival at long-term follow-up.

31 nce in maximum walking distance at long-term follow-up.

32 s were lost to follow-up during the clinical follow-up.

33 ombination of histology and imaging/clinical follow-up.

34 to develop secondary MDS/AML by 10 years of follow-up.

35 ted health-related quality of life at 1-year follow-up.

36 ses of overweight were identified during the follow-up.

37 .3) less of their maximum weight lost across follow-up.

38 and all were considered disease free at last follow-up.

39 is common and mandates continued endoscopic follow-up.

40 Thirty patients (39.0%) died during follow-up.

41 ained ATL-free after a median of 10 years of follow-up.

42 irds scanned regional lymph nodes during the follow-up.

43 During a mean of 9.8 (SD 1.7) years of follow-up, 10 831 deaths were documented, including 3819

44 ost surgery, less RYGB-patients were lost-to follow-up (12.1% vs 16.5%, P < 0.001) and RYGB resulted

45 At 90-day follow-up, 131 of 226 family members (58.0%) responded p

46 ications were reported under DOAC until last follow-up (14.1 +/- 13 mo).

47 nts required mechanical ventilation; at last follow-up, 16 were extubated.

48 ing 2.3 years (interquartile range, 1.0-4.3) follow-up, 160 patients experienced the primary end poin

49 with incident HF in FHS (174 HF events, mean follow-up 19 [limits, 0.2-23.7] years).

50 (P = .002), but declined after 12 months of follow-up (2 [0-4]) (P < .001).

51 ted, with follow-up through May 2018 (median follow-up, 2.63 years).

52 with incident ASCVD (n = 1386 events; median follow-up, 25.2 years; hazard ratio [HR], 1.06 [95% CI,

53 n in 2017 by an on-call junior resident were followed up (257 patients).

54 During up to 21 years of follow-up, 30,389 (38%) participants died, corresponding

55 At last follow-up, 41 patients (80%) were alive and disease-free

56 After 440 person-years of follow-up, 44% of YBMSM initiated PrEP through the study

57 During 20 years of follow-up, 462 individuals developed dementia (mean age

58 In 47.5 million person-years of follow-up, 49,955 (2.3%) women were diagnosed with IHD.

59 During a median 10.0 years of follow-up, 52,251 major vascular events (MVEs), includin

60 At 96 months median follow-up, 94% versus 12% remained MRD free.

61 zed the occurrence of all-cause death during follow-up according to tricuspid annular plane systolic

62 er-based physical activity volume at 3-month follow-up adjusted for sex, 5-year age group, and genera

63 enicity of an initial 2-dose RZV schedule by following-up adults vaccinated at >=60 YOA and by modeli

64 Median follow-up after diagnosis was 34 months (IQR: 17 to 54 m

65 The minimal duration of follow-up after end of therapy was two months.

66 Early, structured telephone follow-up after hospitalization for heart failure can in

67 (12%) but did not increase in frequency over follow-up after implant (P=0.47).

68 .5 (20/63 Snellen equivalent) at most recent follow-up after lens replacement.

69 Incident LSILs and HSILs were common during follow-up among HIV-positive MSM without dysplasia at ba

70 Median follow-up among survivors was 11 years.

71 atients still had a functional graft at last follow up and 9 (18.8%) pancreas grafts were lost due to

72 from patients with a minimum of 6 months of follow-up and at least 2 good-quality SD-OCT scans and 2

73 More frequent follow-up and diligent home monitoring is recommended fo

74 lty on all-cause mortality during 6 years of follow-up and incident comorbidity during 4 years of fol

75 ization for heart failure can increase 7-day follow-up and reduce in-person visits with comparable 30

76 to prevent readmissions through OPAT clinic follow-up and to further assess factors associated with

77 Control and treatment arm loss to follow-up and withdrawal were 24% and 23%, respectively.

78 These patients may require aggressive follow-up and/or adjuvant therapy to mitigate their poor

79 basis of study-specific definitions) during follow-up, and code transmission test scores.

80 rm costs associated with device replacement, follow-up, and healthcare utilization were sourced from

81 other recommendations related to treatment, follow-up, and palliative care from the 2018 version of

82 ents who were English speaking, consented to follow-up, and were randomized between December 11, 2017

83 A follow-up assessment at age 6-10 years of a multicentre

84 In the current study, we performed a 1-year follow-up assessment of the same muscle with repeat MRI

85 ospitalized for bronchiolitis, there was 88% follow-up at 3 years, and 31% had recurrent wheezing.

86 Median follow-up at the time of data cutoff was 2.3 months (IQR

87 Patients were followed up at 3, 6, 9, 12, 15, and 18 months after rand

88 ted with an increase in mortality at longest follow-up available (432/1,375 [31%] vs 330/1,295 [25%];

89 During follow-up, average SBP was 135 mm Hg (125-145).

90 The mean follow-up before peri-implantitis diagnosis was 99.47 +/

91 Two practices were lost to follow-up but provided some outcome data.

92 The patients were followed up by questionnaires on urinary symptoms, sexua

93 Follow-up care was coordinated with local physicians.

94 initiation of nivolumab treatment, the first follow-up chest CT scan was performed and showed new fin

95 We conducted a prospective long-term follow-up cohort study included 263 KTRs with grafts fun

96 Patients were masked until follow-up completion.

97 Follow-up continued until November 26, 2019.

98 m after the blood draw through to the end of follow-up, contrasting vaccine recipients with different

99 rable pattern of calvarial morphology to the follow up CT data could be obtained.

100 In addition, follow up CT scans from 11 pneumonia patients showed ful

101 rtile range]: 3 [4] vs 5 [5]; p = 0.468) and follow-up CT (26 [18] vs 19 [12]; p = 0.352) were simila

102 hemorrhage under antiplatelet treatment and follow-up CT at 24 +/- 12 hours were included.

103 tudy design limitations, and only short-term follow-up data.

104 Over a mean of 182.6 (88.6) follow-up days (min-max: 0-364 days), 22 TEAEs were repo

105 Twelve (27%) of 45 patients with > 90 day follow up discontinued NSBB, most commonly for hypotensi

106 The mean follow-up duration of patients was 19.2 +/- 21.3 months

107 Five trials were included; follow-up duration ranged from 12 to 15 months after PCI

108 is limited by a small sample size and short follow-up duration, and determination of clinical effica

109 sy were enrolled as controls and had similar follow-up during an 18-month period.

110 Four patients were lost to follow-up during the clinical follow-up.

111 from 11 European countries within a 20-year follow-up (ECRHS and SAPALDIA cohorts).

112 We estimated that a single follow-up examination at the end of the first year after

113 nic CSC at baseline and 36 months of regular follow-up examinations were retrospectively enrolled.

114 During the follow-up examinations, dementia was diagnosed in 61 per

115 At last follow-up, eyes that returned to OR and control eyes wer

116 -month postsurgical lung cancer surveillance follow-up (Figs 2, 3).

117 id-resistant pulmonary TB were recruited and followed up for 24 months.

118 ed on protein and glycemic index content and followed up for 26 wk.

119 0 ug, n = 201) or placebo (n = 199) and were followed up for 72 weeks.

120 ars [SD 13.8]) were enrolled in the DCSS and followed up for a median of 9.7 years (IQR 5.8-13.6).

121 Women and men were followed up for recurrent MI, recurrent CHD events (ie,

122 I, 6.3-21.7]; P=0.008) and 11.6 units during follow-up ([Formula: see text], 11.6 [95% CI, 4.1-19.2];

123 invasive breast cancer from 1990 onward with follow-up from the Breast Cancer Association Consortium.

124 A total of 324 healthy infants were followed up from birth to age 3 years.

125 op in a simulated shopping market as well as follow up functional magnetic resonance imaging (fMRI) i

126 a included adult patients with postoperative follow-up >180 days and no other glaucoma-related surger

127 e predictive of tooth loss after a long-term follow-up (>10 years) in patients with periodontitis.

128 With up to 14 years of follow-up, high-risk adenomas were associated with an in

129 patients had true-negative findings based on follow-up imaging for a minimum of 1 year.

130 maging-proven ICH, available DNA and 6-month follow-up in an observational cohort study (CROMIS-2).

131 ew and preexisting DM, but only persisted at follow-up in preexisting DM in patients with HIV-1 infec

132 dentify key demographic factors and modes of follow-up in surgical survey response.

133 ent kidney transplantation and were actively followed up in two hospitals in Paris on March 1st, 2020

134 Follow-up included standard cystoscopic, radiological, a

135 e were 1165 deaths over a mean 10.1 years of follow-up, including 406 CVD and 283 cancer deaths.

136 of cardiovascular and renal disease events, follow-up information was obtained and confirmed by revi

137 ency and F-MALE and therefore close and long follow-up is advisable.

138 nce after anastomotic leakage throughout the follow-up is mandatory.

139 Follow-up is ongoing for long-term outcomes, including e

140 Data collection for long-term follow-up is ongoing, but the trial is closed to recruit

141 so compared with inactive control at 6-month follow-up (k = 10; n = 738; SMD = -0.45, 95% CI -0.82 to

142 hs (range, 8-219 months), and median imaging follow-up lasted 41 months (range, 0-189 months).

143 Median clinical follow-up lasted 95 months (range, 8-219 months), and me

144 At follow-up, liver stiffness measured with TE was similar

145 During follow-up (mean 3.8 years [SD 1.3]), 1069 people progres

146 At last follow-up (mean, 20 months), of the entering 43 patients

147 During follow-up (median 516 days), the combined endpoint of ca

148 d 771 incident cases of breast cancer during follow-up (median time: 5.2 years).

149 icipants provided a baseline and one or more follow-up MoCA or DSST scores, of whom 4456 were assigne

150 asia) that had undergone baseline and 1-year follow-up MRI and flortaucipir PET.

151 After 3 years of follow-up (n = 1,775, 9 RCTs), all-cause mortality was s

152 tion-based patient cohort with full clinical follow-up (n = 928), we investigated whether molecular s

153 d between November 2015 and April 2016, with follow-up occurring in 459 in the intervention group and

154 diovascular hospitalizations during a median follow up of 9.6 years.

155 At the median follow-up of 1 year, high-certainty evidence showed that

156 Over a median follow-up of 10.2 years, mortality was highest for myoca

157 After a median follow-up of 11 years (range 1 mo-25 yrs), symptomatic r

158 n age was 42.00 +/- 5.48 years, with average follow-up of 11.70 +/- 11.38 months.

159 At a median follow-up of 12 months, the objective response rate to i

160 After a mean follow-up of 12 months, the safety index was mean 1.40 +

161 At a median follow-up of 12.3 months (range, 7.0 to 32.3), 57% of th

162 With minimum post-random assignment follow-up of 13.5 months, median PFS was longer with con

163 al conducted from 2008 to 2012 over a median follow-up of 17.0 months in 966 sites (52 countries).

164 At a median follow-up of 18 months, overall survival was 95% and dis

165 20 (60%); 20 (10%) developed symptoms during follow-up of 2.8 +/- 3.0 years.

166 At a median follow-up of 24.2 months in treatment-naive patients and

167 Over a median follow-up of 24.5 (interquartile range, 14.8-33.4) month

168 s of 54 patients were assessed with a median follow-up of 28 months.

169 As of July 2, 2019, at a median follow-up of 28.4 months (IQR 17.7-36.8), median recurre

170 After a median follow-up of 3.1 years, the achieved LDL-C concentration

171 Over a mean follow-up of 3.7 +/- 2.9 years, there were 208 CV or dea

172 tudy within the PREDIMED Study during median follow-up of 3.8 y.

173 median time from discharge to last recorded follow-up of 30 days (interquartile range [IQR], 17-46 d

174 Over a mean follow-up of 30 months, women had a lower risk of MACE (

175 At a median follow-up of 31.4 mo, median overall survival was 13.3 m

176 (ARUBA), randomisation was halted at a mean follow-up of 33.3 months after a prespecified interim an

177 With mean follow-up of 4.8 years (range, 1-7 years), outcomes were

178 After a median follow-up of 42 months (IQR 22-67), 33 (28%) of the 116

179 During a median follow-up of 43 (3-57) months after DAA start, 36 of 452

180 At a mean follow-up of 43+/-23 months, there was no difference in

181 With a median follow-up of 44 months (26-53), 4-year event-free surviv

182 At a median follow-up of 44 months (IQR 20-61), overall survival at

183 During median follow-up of 5.4 (IQR 5.1-5.9) years, 8828 participants

184 pathologic femoral neck fracture with a mean follow-up of 533 days +/- 689.

185 Another 11 patients with a median follow-up of 54 months (range, 15-138 months) were diagn

186 At a median follow-up of 6.6 years, there were 8 major adverse event

187 At a median follow-up of 70 months, rates of 5-year overall survival

188 At a median follow-up of 71.5 months (IQR 71.3 to 71.7), the primary

189 ith mean age of 48.0 +/- 18.0 years and mean follow-up of 78.6 +/- 42.2 months were included.

190 he study included 432 patients with a median follow-up of 8.65 years.

191 logous: n = 676) participated, with a median follow-up of 9.3 years from BMT.

192 In the 5-year follow-up of a phase 3 trial involving patients who had

193 visits and of these, 93 completed a 6-month follow-up of home and clinical visits.

194 Longer-term follow-up of patients implanted with INTACS is important

195 controlled disease according to imPERCIST5; follow-up of patients showed that 22% of these patients

196 clinical implications for the management and follow-up of patients.

197 negative on 15 March developed symptoms over follow-up; of these, 3 were re-tested and 2 were positiv

198 e excluded if they had less than 3 months of follow-up on either drug.

199 During follow-up, opioid injecting (odds ratio [OR], 0.95; 95%

200 progression, unacceptable toxicity, loss to follow-up, or withdrawal of consent.

201 With a 2.9-year median follow-up, OS improved from 33% (46-68%) for HCT before

202 ects of SHBG in UK Biobank (N = 334 977) and followed-up our top findings using two-sample MR analyse

203 lts aged 40-78 y at baseline (1993-1997) and followed up over 1998-2000 (mean +/- SD: 3.7+/-0.7 y) in

204 All patients were followed up over a 1-year period (study end date, March

205 23 and cardiac magnetic resonance at 10-year follow-up, participants with higher FGF23 levels were mo

206 At 36 months follow-up, patient level analysis showed that REC in the

207 During follow-up, patients exhibited a positive clinical and ne

208 After up to 6 years of follow-up, patients treated with mite allergoid required

209 er, a larger number of patients and a longer follow-up period are needed to confirm our results.

210 iTIs Study (VEKTIS), 142 entered the 8-month follow-up period during which CsA CE patients remained o

211 ich 371 (36%) received an RT during a median follow-up period of 2.5 (1.4-4.1) years.

212 ch was well tolerated in all patients over a follow-up period of 4 wk.

213 The mean follow-up period of all eyes was 38.4 +/- 11.2 months (r

214 ssociated optic pathway gliomas (OPGs) and a follow-up period of at least 10 years in a cohort of chi

215 At the data cutoff (Aug 7, 2019), the median follow-up period was 12.9 months (IQR 6.2-22.9).

216 iod at high risk of HIV infection during the follow-up period when not taking PrEP; and finally, an i

217 During the 9-wk follow-up period, patients recorded daily ratings of fac

218 d (C(T) ) of <35 or seroconverted during the follow-up period, yielding an attack rate on board of 85

219 efined as event occurrence status during the follow-up period.

220 ersus alive 1 year after ECG) over a 25-year follow-up period.

221 grafts (FGG) at implant sites over a 3-month follow-up period.

222 th a health-care provider within a specified follow-up period.

223 sation phase and Vital Projects Fund for the follow-up phase.

224 f 250 TAVR patients in whom baseline Zva and follow-up QOL was prospectively assessed using EuroQOL-5

225 alysis population who completed at least one follow-up questionnaire included 110 (93%, 110/118) in t

226 Current weight was self-reported on follow-up questionnaires approximately every 2 years.

227 iated PrEP and had perceived HIV risk during follow-up reported taking PrEP, but one-third had drug c

228 4% of their initial weight lost at 1 and 2 y follow-up, respectively.

229 d glaucoma surgery at 1-, 5-, and 8-years of follow-up, respectively.

230 27 (15%) experiencing outcome events during follow-up, respectively.

231 echnical information, treatment outcomes and follow-up results were collected.

232 Follow-up samples were studied to evaluate within-patien

233 (SCD-HeFT 10 Year Follow-up [SCD-HeFT10 Yr]; NCT01058837).

234 Conclusion Long-term MRI follow-up showed that 78% of hepatocellular adenomas had

235 a to identify which mutations to target in a follow-up single-cell sequencing experiment, thereby dec

236 providers can adhere to frequent, consistent follow-up so antiviral therapy may begin at the earliest

237 orn with a major congenital anomaly with the follow-up starting from birth that were published in the

238 selection, procedure selection, duration of follow-up, statistical analysis, and publication require

239 and 43,911 men from the Health Professionals Follow-up Study (1986-2016) who were free of CVD and can

240 and 41,412 men from the Health Professionals Follow-up Study (HPFS; 1986-2016) who were free of T2D,

241 A follow-up study confirmed that immunization against only

242 An observational follow-up study was carried out for 1 year following vac

243 d with lower lymphocyte counts and in silico follow-up suggests a potential effect on T-lymphocytes a

244 As a replication, we performed follow-up targeted sequencing of ASH1L in additional 524

245 At 12 months of follow-up, the probabilities of therapy discontinuation

246 )F-FET PET had a significantly longer stable follow-up (threshold of TBR reduction relative to baseli

247 During follow-up through 2014, a total of 8,354 participants di

248 reflux surgery for GERD in 2000 to 2012 with follow-up through 2014, and the outcome was surgical rei

249 and HCV RNA prevalence were evaluated, with follow-up through May 2018 (median follow-up, 2.63 years

250 After a median [IQR] follow-up time of 21 [20-22] y, 2131 participants had be

251 severe liver disease at 5, 10, and a maximum follow-up time of 27 years.

252 During a median follow-up time of 62.5 months, 564 of the 3,478 particip

253 After a median follow-up time of 696 days (interquartile range 1201 d),

254 Over a median follow-up time of 7 years, 74 of 103 treated patients (7

255 The median (interquartile range) follow-up time was 4.6 (2.7-7.1) years.

256 Furthermore, at follow-up, time to peak in metabolic responders increase

257 extremely intriguing tool since it assumes a follow up to treatments to survey the accomplishment of

258 2002-2018) of patients with a first ICH with follow-up to 10 years, we determined the long-term risks

259 m July 7, 2016, through April 17, 2018, with follow-up to December 11, 2018.

260 After 4 years of follow-up univariable and multivariate model analysis sh

261 pitals between April 2017 and May 2019, with follow-up until August 2019.

262 between 2006 and 2010, and participants were followed up until 2016.

263 Patients were followed-up until discharge from hospital for a median o

264 ential trial participants, and for long-term follow-up; use of prescreening to facilitate rapid recru

265 function was assessed at baseline and during follow-up using the Montreal Cognitive Assessment (MoCA)

266 In eyes with 4-year follow-up, VA changes from baseline (ETDRS letters) were

267 The final follow-up visit was completed in January 2020.

268 th HIV-negative (38% at baseline, 30% at the follow-up visit) and HIV-positive (27% at baseline, 35%

269 nd HIV-positive (27% at baseline, 35% at the follow-up visit) women.

270 At each annual follow-up visit, all subjects underwent ophthalmic exami

271 randomly assigned and attended at least one follow-up visit, compared unintended pregnancy incidence

272 t baseline (after randomization) and at each follow-up visit.

273 duced by 30% below baseline on 2 consecutive follow-up visits after 3 months.

274 At 5 follow-up visits in participants' homes, swabs to detect

275 the clinical booking system (new patient and follow-up visits) for all clinical provider types of the

276 Median follow-up was 13.2 months (IQR 7.3-20.4) as of data cuto

277 Median follow-up was 15.8 years.

278 The median follow-up was 17.8 months (IQR 11.6-21.3).

279 Median follow-up was 19.0 months (IQR 15.0-23.4).

280 Median follow-up was 30 days (IQR 27-83).

281 Median follow-up was 38.3 months (IQR 20.7-46.1, range 0-138.0;

282 ipants underwent randomization, and the mean follow-up was 4.6 years.

283 The median follow-up was 44 mo.

284 ty-five patients were included with a median follow-up was 5.8 years.

285 The median follow-up was 59 months, and overall and major response

286 Mean recipient follow-up was 6.3 years, during which 287 death-censored

287 ]), and favorable clinical response at early follow-up was 61.0% and 55.8%, respectively (difference,

288 p and incident comorbidity during 4 years of follow-up was assessed among 598 HIV-positive and 550 co

289 End of follow-up was June 30, 2018.

290 4 to May 2006 for baseline measurements, and follow-up was performed 48 months later.

291 Although follow-up was shorter for aP5 cohorts, their risk did no

292 During 5,291,518 person-years of follow-up, we documented 15,837 incident CVD cases, incl

293 ys and 1 year and all-cause mortality during follow-up were evaluated.

294 invasive glaucoma surgery, and <=90 days of follow-up were excluded from outcomes analysis.

295 duction treatment and a minimum 12 months of follow-up were selected (n = 2263).

296 ficial effects of STN-DBS on NMS at 36-month follow-up which also correlated with quality of life imp

297 es (33%) had stable visual fields throughout follow-up, while 8 eyes (67%) had slow-to-moderate progr

298 Class 1 presented during long-term follow-up with a low graft failure rate: 5% class 1, vs

299 t diagnosis, 46.2 [SD 9.1] years) during the follow-up with an incidence rate of 5.9 per 100 000 obse

300 reatment period and 10-fold lower during the follow-up year (n = 18, P = .03).